Invex Therapeutics (ASX:IXC) Interest Expense: A$0.00 Mil (TTM As of Dec. 2025)


What is Invex Therapeutics Interest Expense?

Invex Therapeutics ASX:IXC -9.09% Interest Expense is A$0.00 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Invex Therapeutics's interest expense for the six months ended in Dec. 2025 was A$ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Invex Therapeutics's Operating Income for the six months ended in Dec. 2025 was A$ -0.84 Mil. Invex Therapeutics's Interest Expense for the six months ended in Dec. 2025 was A$ 0.00 Mil. Invex Therapeutics has no long-term debt (1). The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Invex Therapeutics  (ASX:IXC) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Invex Therapeutics's Interest Expense for the six months ended in Dec. 2025 was A$0.00 Mil. Its Operating Income for the six months ended in Dec. 2025 was A$-0.84 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2025 was A$0.00 Mil.

Invex Therapeutics's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as

Invex Therapeutics had no long-term debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Invex Therapeutics Ltd has no debt.

Invex Therapeutics Interest Expense Historical Data

* Premium members only.

The historical data trend for Invex Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Invex Therapeutics Interest Expense Chart

Invex Therapeutics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Interest Expense
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Invex Therapeutics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Invex Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of A$0.00 Mil mean?
Invex Therapeutics (ASX:IXC) has a Interest Expense of A$0.00 Mil as of Dec. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on Invex Therapeutics and its competitors.
Is Invex Therapeutics' Interest Expense too high?
Invex Therapeutics' current Interest Expense is A$0.00 Mil.
How does Invex Therapeutics' Interest Expense compare to VRTX and REGN?
Invex Therapeutics' Interest Expense of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Invex Therapeutics and its competitors. Invex Therapeutics's current Interest Expense is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invex Therapeutics stock overvalued right now?
Invex Therapeutics (ASX:IXC) has a current Interest Expense of A$0.00 Mil. The current Interest Expense is A$0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Invex Therapeutics (ASX:IXC), the current Interest Expense is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Invex Therapeutics Business Description

Address c/- Automic Group, Level 5, 191 St Georges Terrace, Perth, WA, AUS, 6000
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.